



OPEN ACCESS

EDITED BY

Laisa Liane Paineiras-Domingos, Federal University of Bahia, Brazil

REVIEWED BY

Seyed Mohammad Mahdi Moshirian Farahi,

Carleton University, Canada Samson Femi Agberotimi, North-West University, South Africa

*CORRESPONDENCE

Shougang Sun sunshg806@126.com

SPECIALTY SECTION

This article was submitted to Psychology for Clinical Settings, a section of the journal Frontiers in Psychology

RECEIVED 22 August 2022 ACCEPTED 25 October 2022 PUBLISHED 16 November 2022

CITATION

Zou Q, Tang Y, Jiang C, Lin P, Tian J and Sun S (2022) Prevalence of anxiety, depressive and insomnia symptoms among the different groups of people during COVID-19 pandemic: An overview of systematic reviews and meta-analyses. *Front. Psychol.* 13:1024668. doi: 10.3389/fpsyg.2022.1024668

COPYRIGHT

© 2022 Zou, Tang, Jiang, Lin, Tian and Sun. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

Prevalence of anxiety, depressive and insomnia symptoms among the different groups of people during COVID-19 pandemic: An overview of systematic reviews and meta-analyses

Qi Zou¹, Yuning Tang¹, Cheng Jiang¹, Pengyang Lin¹, Jinhui Tian² and Shougang Sun^{1*}

¹Department of Cardiology, Lanzhou University Second Hospital, Lanzhou, China, ²Evidence-Based Medicine Center of Lanzhou University, Lanzhou, China

Since the pandemic of the novel 2019 coronavirus disease (COVID-19), in addition to the harm caused by the disease itself, the psychological damage caused to the public by the pandemic is also a serious problem. The aim of our study was to summarize the systematic reviews/meta-analyses (SRs/MAs) of the prevalence of anxiety, depression and insomnia in different populations during the COVID-19 pandemic and to qualitatively evaluate these SRs/MAs. We searched the Cochrane Library, PubMed and Web of Science to obtain SRs/MAs related to anxiety, depression, and insomnia in different populations during the COVID-19 pandemic. The main populations we studied were healthcare workers (HCWs), college students (CSs), COVID-19 patients (CPs), and the general populations (GPs). A subgroup analysis was performed of the prevalence of psychological disorders. A total of 42 SRs/MAs (8,200,330 participants) were included in calculating and assessing the prevalence of anxiety, depression, and insomnia in these populations. The results of subgroup analysis showed that the prevalence of anxiety in different populations were: HCWs (20-44%), CSs (24-41%), CPs (15-47%), and GPs (22-38%). The prevalence of depression were: HCWs (22-38%), CSs (22-52%), CPs (38-45%), and GPs (16-35%), statistically significant differences between subgroups (p < 0.05). The prevalence of insomnia were: HCWs (28– 45%), CSs (27-33%), CPs (34-48%), and GPs (28-35%), statistically significant differences between subgroups (p < 0.05). The comparison revealed a higher prevalence of psychological disorders in the CP group, with insomnia being the most pronounced. The methodological quality of the included SRs/MAs

was then evaluated using AMSTAR 2 tool. The results of the methodological quality evaluation showed that 13 SRs/MAs were rated "medium," 13 were rated "low," and 16 were rated "very low." Through the subgroup analysis and evaluation of methodological quality, we found a higher prevalence of insomnia than anxiety and depression among the psychological disorders occurring in different populations during the pandemic, but the sample size on insomnia is small and more high-quality studies are needed to complement our findings.

KEYWORDS

COVID-19, anxiety, depression, insomnia, systematic review, AMSTAR 2

Introduction

Since the outbreak of the COVID-19 pandemic in December 2019, the suddenness of the COVID-19 pandemic and the lack of effective preventive measures at the beginning has led to the rapid spread of the pandemic worldwide, and by the end of Jun 2022, the COVID-19 pandemic outbreak has caused about 50 million infections and 6 million deaths in more than 200 countries worldwide, resulting in incalculable human casualties and economic losses. As a result, the enormous toll of the COVID-19 pandemic has led to a significant increase in the incidence of psychological disorders in different segments of society, the most common of which are anxiety, depression, and insomnia (Bao et al., 2020). Psychological disorders occur mainly in healthcare workers (HCWs), college students (CSs), COVID-19 patients (CPs), and the general populations (GPs), who are also the groups more severely affected by the pandemic (Alsubaie et al., 2019; Chen Q. et al., 2020; Pfefferbaum and North, 2020; Wang C. et al., 2020; Zhang et al., 2020).

The fact that the CPs are already infected themselves, coupled with the increasing number of deaths each day, has led to anxiety for their lives and panic, coupled with being in quarantine and isolated from the outside world, creating a severe sense of isolation (Alsubaie et al., 2019). The large number of casualties caused by the pandemic has increased the burden and psychological stress on HCWs. In addition, many HCWs have unfortunately also been infected due to prolonged close contact with the CPs (Wang J. et al., 2020). It has been reported that more than 17,000 HCWs have died from COVID-19 (Huang et al., 2020; Wu et al., 2020). The prolonged pandemic has also caused serious psychological disorders among CSs. The lack of knowledge about the pandemic and excessive attention to internet information has increased anxiety and depression among some students, in addition to the lack of physical exercise and long hours of screen study, with senior students worrying about their graduation (Han et al., 2020). Since most factories and companies and other related places cannot function normally during the pandemic, a large number of people are isolated from home of economic resources and lack normal social communication, they are prone to psychological disorders. In addition, the shortage of food with high prices caused severe anxiety and depression in the minds of the people (Kawohl and Nordt, 2020; Lone and Ahmad, 2020; Browning et al., 2021).

For the above, there have been many systematic reviews/meta-analyses (SRs/MAs) incorporating different cross-sectional studies to calculate the prevalence of some common psychological disorders in different populations during the pandemic, especially the pooled prevalence of anxiety, depression, and insomnia. There are many SRs/MAs on the majority of anxiety, depression, and insomnia in different populations during the COVID-19 pandemic, but these reviews differ in quality and design. Therefore, it is needed to assess the methodological quality of these SRs/MAs, summarize the evidence for the important outcomes included in the SRs/MAs, state the conclusions of these SRs/MAs and combine these results to produce more accurate data for a large sample size.

Materials and methods

Sources of literature and search strategy

To identify the included literature, we searched for SRs/MAs published in the Cochrane Library, PubMed and Web of Science from December 2019 to June 2022 related to our study topic, without applying any language restrictions and the search terms included all identified keywords ("2019n-CoV," "new coronavirus pandemic," "COVID-19," "anxiety," "depression," "insomnia," "sleep disorders," "psychological impact") and adjusted for each database. The detailed search strategy is shown in **Figure 1**.

#1 COVID-19 [Mesh] #2 2019n-CoV OR COVID-19 OR new coronavirus epidemic OR **SARS-COV-2** #3 anxiety [Mesh] #4 depression [Mesh] #5 insomnia [Mesh] #6 sleep disorders [Mesh] #7 psychological impact [Mesh] #8 anxiety OR depression OR insomnia OR sleep disorders OR psychological impact #9 meta-analysis [MeSH] #10 systematic review [Mesh] # 11(#1 OR #2) AND (#3 OR #4 OR #5 OR #6 OR #7 OR #8) AND (#9 OR #10)

Search strategies.

Inclusion and exclusion criteria

Systematic reviews /MAs were included if they met the following criteria: (1) published since the outbreak of COVID-19 in December 2019. (2) the studies included in the report involved study populations that experienced the COVID-19 pandemic. (3) the determination of anxiety, depression, and insomnia in the study populations included in the report was subject to the use of an authoritative assessment tool for psychological disorders. (4) the prevalence of anxiety, depression, or insomnia in the study population was provided. (5) the type of studies included in the report were cross-sectional studies. (6) The type of publication of the literature is systematic reviews/metaanalyses. We excluded literature reviews that (1) used informal and subjective methods to collect and interpret evidence, reviews, and non-peer reviews; and (2) our study population did not include pregnant mothers, chronic patients, elderly and children, so these populations were excluded from the study.

Study selection

All the retrieved literature was imported into NoteExpress software to identify and remove duplicate studies. Then the

titles and abstracts of the papers were browsed to initially exclude literature that was far from the purpose of our research. Two evaluators (QZ and YT) then independently read and evaluated the full articles. Those that did not meet the pre-determined inclusion criteria were excluded, with a third evaluator (SS) making the determination when no agreement could be reached on any of them.

Data extraction


Two evaluators (CJ and PL) independently extracted data from the included reports based on a pre-designed Excel spreadsheet for quality assessment and data analysis. The data extraction spreadsheet summarized key characteristics: (1) year of publication and authors; (2) number of included studies; (3) total sample size; (4) outcome indicators and prevalence; (5) quality assessment tools; and (6) journal of publication. When agreement could not be reached on data from the literature, a third evaluator (SS) made the determination. When necessary, additional information was obtained from the original cross-sectional study reports.

Methodological quality assessment

The methodological quality of the included studies was independently evaluated by two evaluators using the AMSTAR 2 tool (Shea et al., 2017). The tool contains 16 entries, of which entries 2, 4, 7, 9, 11, 13, and 15 are vital entries, and the results were classified into 3 levels "satisfied," "partially satisfied," and "not satisfied." AMSTAR 2 tools of satisfied and partially satisfied \geq 70% were considered to be more complete for entry reporting. AMSTAR 2 Scoring Quality Levels. See **Supplementary Table 1** for definitions of quality levels.

Managing overlapping systematic reviews

Some SRs/MAs may have repeatedly included the same study when discussing the same or similar topics. Multiple inclusion of the same study can lead to biased outcome data. Therefore, when conducting evidence summaries, these repeatedly included studies can have a greater impact on our primary outcomes. According to Cochrane's guidance (Higgins et al., 2020), results from all relevant studies should be included if the purpose of the overview is to present and describe the current body of evidence on a topic, so we did not exclude overlapping systematic reviews. However, to avoid greater bias in the final results, we presented the results of the included SRs/MAs using only forest plots and did not pool the results.



Statistical analysis

To investigate the prevalence of anxiety, depression, and insomnia worldwide during the COVID-19 pandemic, we divided the target population into four subgroups (HCWs, CSs, CPs, GPs) and analyzed the prevalence of anxiety, depression, and insomnia in each subgroup. Meta-analysis was performed using Revman 5.4 software, with prevalence and its 95% CI as statistical effect measures. Heterogeneity among the included studies was analyzed using the χ^2 test (test level $\alpha=0.1$), while the magnitude of heterogeneity was quantified by combining I^2 . When $I^2>50\%$ or p<0.10, a random-effects model was used, otherwise a fixed-effects model was used. To evaluate the robustness of the results of group comparisons, we performed statistical tests on the results of group comparisons, suggesting statistically significant differences when the p<0.05. Microsoft Excel 2018 was used to record the relevant data and bubble plot

of the results of the methodological quality assessment of the literature. We used percentages to describe the prevalence of psychological disorders.

Results

Study identification

A total of 848 records were identified with our search. Of these, 635 were screened after the removal of duplicates. After screening titles and abstracts, 436 records were excluded. The full text of the remaining 199 records was retrieved for further scrutiny. Of these, 157 were excluded because they did not fulfill the eligibility criteria. Finally, 42 SRs/MAs ere included in this overview. The study selection process is summarized in Figure 2.

TABLE 1 Characteristics of included systematic reviews (n = 42).

Pappe et al., 2000	Study ID	Study population	Sample size	Included research		Outcomes	Quality assessment tools	
Al Maqbalie al , 2021		1 1			Anxiety	Depression	Insomnia	
Varghese et al., 2021 HCW 17,100 27 33% 32% 38% NA Shusarka et al., 2022 HCW 44,165 23 29% 22% AHRQ Shusarka et al., 2021 HCW 22,380 19 26% 24% STROBE Li et al., 2021 HCW 101,017 70 30% 31% 44% AHRQ Saragih et al., 2021 HCW 53,784 38 40% 37% 44% AHRQ Saragih et al., 2021 HCW 57,430 71 25% """">"""""""""""""""""""""""""""""""	Pappa et al., 2020	HCW	33,062	13	23%	23%	34%	NOS
Situariska et al., 2022 HCW 44,165 23 29% 22% AHRQ Salari et al., 2020 HCW 22,380 19 26% 24% STROBE Li et al., 2021 HCW 101,017 70 30% 31% 44% AHRQ Saragih et al., 2021 HCW 101,017 70 30% 31% 44% AHRQ Saragih et al., 2021 HCW 73,437 65 34% 32% 28% NH Saragih et al., 2021 HCW 57,430 71 25% 28% NH Norhaysti et al., 2021 HCW 149,225 78 35% 35% 35% JBI Salari et al., 2021 HCW 187,506 96	Al Maqbali et al., 2021	HCW	93,112	93	37%	35%	43%	NOS
Salari et al., 2020b HCW 97,333 65 22% 22% NA Marvaldi et al., 2021 HCW 97,333 65 22% 22% 14% NA Marvaldi et al., 2021 HCW 101,017 70 30% 31% 44% AHRQ Saragh et al., 2021 HCW 53,784 38 40% 37% 181 Batra et al., 2021 HCW 57,430 71 25% 78 35% 38% IBI Sarababirbara et al., 2021a HCW 187,506 96 78 35% 35% 38% IBI Sabebi et al., 2021 HCW 187,506 96 78 35% 35% 38% IBI Sabebi et al., 2021 HCW 187,506 96 78 35% 35% 38% IBI Sabebi et al., 2022 HCW 187,506 96 78 35% 35% 38% IBI Sabebi et al., 2022 HCW 98,535 71 35% 36% 36% NOS Jahrami et al., 2022 HCW 98,535 71 35% 38% 35% NOS Jahrami et al., 2021 HCW 34,386 13 56 38% NA Liu et al., 2021 HCW 19,189 117 30% 24% 80% NOS Jahrami et al., 2021 HCW 38,372 21 44% 31% 80% NOS Liu et al., 2021 HCW 38,372 21 44% 31% NOS Deng et al., 2021 CS 13,247 17 32% 52% 27% JBI Clang et al., 2021 CS 14,418,28 89 32% 34% 37% NOS Deng et al., 2021 CS 1,4418,28 89 32% 34% 37% NOS Deng et al., 2021 CS 1,688,619 36 41% 26% JBI Sarababirbara et al., 2021 CS 1,4418,28 39 32% 34% 37% NOS Deng et al., 2021 CS 1,4418,28 39 32% 34% 37% NOS Deng et al., 2021 CS 1,4418,28 39 32% 34% 37% NOS Deng et al., 2021 CS 1,4418,28 39 32% 34% 37% NOS Deng et al., 2021 CS 1,4418,28 39 32% 34% 37% NOS Deng et al., 2021 CS 1,4418,28 39 32% 34% 37% NOS Deng et al., 2021 CS 1,4418,28 39 32% 34% 37% NOS Deng et al., 2021 CS 1,4418,28 39 32% 34% 37% NOS Deng et al., 2021 CS 1,4418,28 39 32% 34% 37% NOS Deng et al., 2021 CS 1,4418,28 39 32% 34% 34% NOS Deng et al., 2021 CS 1,4418,28 39 32% 34% 34% NOS Deng et al., 2021 CS 1,4418,28 39 32% 34% 34% NOS Deng et al., 2021 CS 1,4418,28 39 32% 34% 34% NOS Deng et al., 2021 CS 1,4418,28 39 32% 34% 34% NOS Deng et al., 2021 CS 1,4418,28 39 32% 34% 34% NOS Deng et al., 2021 CS 1,4418,28 39 32% 34% 34% NOS Deng et al., 2021 CS 1,4418,28 39 32% 34% 34% NOS Deng et al., 2021 CS 1,4418,28 39 32% 34% 34% NOS Deng et al., 2021 CS 1,4418,28 39 32% 34% 34% NOS Deng et al., 2021 CS 1,4418,28 39 32% 34% 34% NOS Deng et al., 2021 CS 1,4418,28 39 32% 34% NOS Deng et al., 2021 CP 4,4318 17 33% 2	Varghese et al., 2021	HCW	17,100	27	33%	32%	38%	NA
He He He He He He He He	Ślusarska et al., 2022	HCW	44,165	23	29%	22%		AHRQ
Marvaldi et al., 2021 IICW 101,017 70 30% 31% 44% AHRQ Saragit et al., 2021 HCW 53,784 38 40% 37% 28% IBI Batra et al., 2020 HCW 79,437 65 34% 32% 28% NIII Santabárbara et al., 2021 HCW 149,925 78 35% 35% 36% JAM Salari et al., 2021 HCW 187,966 96	Salari et al., 2020b	HCW	22,380	19	26%	24%		STROBE
Saragih et al., 2021 HCW 53,784 38 40% 37% IBI Batra et al., 2020 HCW 79,437 65 34% 32% 28% NIH Santabárbara et al., 2021 HCW 149,925 78 35% 35% 38% JBI Sabari et al., 2020e HCW 187,506 96 5 35% 35% AMSTAR-2 Sabari et al., 2020e HCW 5,868 7 5 20% 26% JBI Johns et al., 2022 HCW 96,535 71 35% 38% 45% NOS Jahrami et al., 2021 HCW 19,189 117 30% 24% 80 NOS Serrano-Ripoll et al., 2021 HCW 13,486 13 38% A\$ NOS Serrano-Ripoll et al., 2021 CS 13,247 17 32% 52% 27% IBI Mulyadi et al., 2021 CS 1,441,828 89 32% 34% 33% NOS	Li et al., 2021	HCW	97,333	65	22%	22%		NA
Bara et al., 2020 HCW 79,437 65 34% 32% 28% NIH Santabirbara et al., 2021 HCW 57,430 71 25%	Marvaldi et al., 2021	HCW	101,017	70	30%	31%	44%	AHRQ
Santabárbara et al., 2021a HCW 149,925 78 35% 35% 35% 38% BI Sanebi et al., 2021 HCW 187,506 96	Saragih et al., 2021	HCW	53,784	38	40%	37%		JBI
Norhayati et al., 2021 HCW 149,925 78 35% 35% 38% JBI Sahebi et al., 2021 HCW 187,506 96 36% AMSTAR-2 Sahari et al., 2020c HCW 5,868 7 3 36% 36% STROBE Johns et al., 2022 HCW 21,112 55 20% 26% JBI Het et al., 2021 HCW 98,535 71 35% 38% 45% NOS Jahrami et al., 2021 HCW 54,231 44 36% JBI Serrano-Ripoll et al., 2020 HCW 119,189 117 30% 24% ROBINS I Serrano-Ripoll et al., 2021 HCW 38,372 21 44% 31% NA Lite et al., 2021 HCW 38,372 21 44% 31% NA HUW 38,372 21 44% 31% 30% 10% NOS JBI Chang et al., 2021 CS 13,247 17 32% 52% 27% JBI Chang et al., 2021 CS 144,010 16 31% 34% NOS Liyanage et al., 2021 CS 1,088,619 36 41% JBI Santabárbara et al., 2021 CS 4,144 15 35% JBI Santabárbara et al., 2021 CS 4,147 13 26% JBI Santabárbara et al., 2021 CS 4,147 13 37% JBI Santabárbara et al., 2021 CS 4,147 13 37% JBI Santabárbara et al., 2021 CS 4,147 13 37% JBI Santabárbara et al., 2021 CS 1,292,811 84	Batra et al., 2020	HCW	79,437	65	34%	32%	28%	NIH
Sahebi et al., 2021 HCW 187,506 96	Santabárbara et al., 2021a	HCW	57,430	71	25%			JBI
Salari et al., 2020c HCW 5,868 7	Norhayati et al., 2021	HCW	149,925	78	35%	35%	38%	JBI
	Sahebi et al., 2021	HCW	187,506	96			36%	AMSTAR-2
Het et al., 2022 HCW 98,535 71 35% 38% 45% NOS Jahrami et al., 2021 HCW 54,231 44	Salari et al., 2020c	HCW	5,868	7			35%	STROBE
Jahrami et al., 2021 HCW 54,231 44 36% JBI Serrano-Ripoll et al., 2021 HCW 119,189 117 30% 24% ROBINS I Serrano-Ripoll et al., 2021 HCW 13,486 13 38% NA Liu et al., 2021 HCW 38,372 21 44% 31% AHRQ Mulyadi et al., 2021 CS 144,010 16 31% 34% 32% NOS Deng et al., 2021a CS 1,441,828 89 32% 34% 33% NOS Liyanage et al., 2021 CS 1,088,619 36 41% 18I Luc et al., 2021 CS 1,088,619 36 41% 18I Santabárbara et al., 2021 CS 1,041 15 35% 18I Santabárbara et al., 2021 CS 4,147 13 24% 22% 41RQ Labier al., 2021 CS 128,536 <td>Johns et al., 2022</td> <td>HCW</td> <td>21,112</td> <td>55</td> <td>20%</td> <td>26%</td> <td></td> <td>JBI</td>	Johns et al., 2022	HCW	21,112	55	20%	26%		JBI
Scerano-Ripoll et al., 2020 HCW 119,189 117 30% 24% ROBINS I Serrano-Ripoll et al., 2021 HCW 13,486 13	Hu et al., 2022	HCW	98,535	71	35%	38%	45%	NOS
Serrano-Ripoll et al., 2021 HCW 13,486 13	Jahrami et al., 2021	HCW	54,231	44			36%	JBI
Liu et al., 2021a HCW 38,372 21 44% 31% 27% JBI Mulyadi et al., 2021 CS 13,247 17 32% 52% 27% JBI Chang et al., 2021 CS 144,010 16 31% 34% 30% NOS Deng et al., 2021a CS 1,441,828 89 32% 34% 33% NOS Liyanage et al., 2021a CS 1,088,619 36 41% JBI Luo et al., 2021 CS 1,292,811 84 26% JBI Santabárbara et al., 2021d CS 4,147 13 35% 27% JBI Chang et al., 2021 CS 4,147 13 37% JBI Chang et al., 2021 CS 1,171,10 8 28% JBI Chang et al., 2021 CS 1,285,36 38 24% JBI Chang et al., 2021 CS 1,285,36 38 24% JBI Chang et al., 2021 CS 1,285,36 38 24% JBI Chang et al., 2021 CP 1,891,59 68 15% 16% JBI Chang et al., 2021 CP 4,381 22 38% 38% 48% MNOS Liu et al., 2021 CP 4,381 22 38% 38% 48% MNOS Chen et al., 2020 CP 2,206 8 44% JBI Chang et al., 2021 CP 3,153 31 27% 35% 38% 48% MNOS Chen et al., 2021 CP 3,206 38 44% JBI Chang et al., 2020 CP 2,206 38 44% JBI Chang et al., 2021 CP 3,381 22 38% 38% 48% MNOS Chen et al., 2020 CP 2,206 38 44% JBI Chang et al., 2021 CP 3,4381 22 38% 38% 48% MNOS Chen et al., 2020 CP 2,206 38 44% JBI Chang et al., 2020 CP 3,206 38 44% JBI Chang et al., 2020 CP 3,206 38 48% MNOS Chen et al., 2020 CP 3,206 34 45% JBI Chang et al., 2020 CP 3,206 34 45% JBI Chang et al., 2020 CP 3,206 38 44% JBI Chang et al., 2020 CP 3,206 34 45% JBI Chang et al., 2020 CP 3,206 34 45% JBI Chang et al., 2020 CP 3,206 34 45% JBI Chang et al., 2020 CP 3,206 34 45% JBI Chang et al., 2020 CP 3,206 34 45% JBI Chang et al., 2020 CP 3,206 34 58 58% JBI Chang et al., 2020 CP 3,206 34 58 58% JBI Chang et al., 2020 CP 3,206 35% JBI Ch	Serrano-Ripoll et al., 2020	HCW	119,189	117	30%	24%		ROBINS I
Mulyadi et al., 2021 CS 13,247 17 32% 52% 27% JBI Chang et al., 2021 CS 144,010 16 31% 34% NOS Deng et al., 2021a CS 1,441,828 89 32% 34% 33% NOS Liyanage et al., 2021 CS 1,088,619 36 41% JBI JBI Luo et al., 2021 CS 1,292,811 84 26% JBI Santabárbara et al., 2021c CS 6,141 15 35% JBI Santabárbara et al., 2021c CS 4,147 13 37% JBI Zhang et al., 2021 CS 4,147 13 24% 22% AHRQ Lasheras et al., 2021 CS 11,710 8 28% 22% AHRQ Zhai et al., 2021 CS 128,536 38 24% NOS NA Deng et al., 2021b CP 5,153 31 47% 45% 34% NOS	Serrano-Ripoll et al., 2021	HCW	13,486	13			38%	NA
Chang et al., 2021 CS 144,010 16 31% 34% NOS Deng et al., 2021a CS 1,441,828 89 32% 34% 33% NOS Liyanage et al., 2021 CS 1,088,619 36 41% JBI Luo et al., 2021 CS 1,292,811 84 26% JBI Santabárbara et al., 2021 CS 6,141 15 35% JBI Santabárbara et al., 2021 CS 4,147 13 37% JBI Zhang et al., 2021 CS 203,678 31 24% 22% AHRQ Lasheras et al., 2020 CS 11,710 8 28% JBI Zhai et al., 2022 CS 128,536 38 24% NA Deng et al., 2021 CP 189,159 68 15% 16% JBI Liu et al., 2021 CP 4,381 22 38% 38% 48% MNOS Lao et al., 2021 CP 4,381 22 38% 38% 48% MNOS Lao et al., 2020 CP 2,206 8 44% NA Liu et al., 2021 GP 146,139 71 33% 28% 30% NOS Chen et al., 2022 GP 201,953 82 34% STROBE Zhang et al., 2022 GP 203,52 25 22% 16% MMAT Salari et al., 2022 GP 20,352 25 22% 16% MMAT Salari et al., 2020 GP 44,531 17 32% 34% STROBE Santabárbara et al., 2021 GP 56,679 43 25% STROBE Santabárbara et al., 2021 GP 56,679 43 25% STROBE	Liu et al., 2021a	HCW	38,372	21	44%	31%		AHRQ
Deng et al., 2021a CS 1,441,828 89 32% 34% 33% NOS Liyanage et al., 2021 CS 1,088,619 36 41%	Mulyadi et al., 2021	CS	13,247	17	32%	52%	27%	JBI
Liyanage et al., 2021 CS 1,088,619 36 41%	Chang et al., 2021	CS	144,010	16	31%	34%		NOS
Luo et al., 2021 CS 1,292,811 84 26% JBI Santabárbara et al., 2021d CS 6,141 15 35% JBI Santabárbara et al., 2021c CS 4,147 13 37% JBI Zhang et al., 2021 CS 203,678 31 24% 22% AHRQ Lasheras et al., 2020 CS 11,710 8 28% JBI Zhai et al., 2022 CS 128,536 38 24% NA Deng et al., 2021b CP 5,153 31 47% 45% 34% NOS Cénat et al., 2021 CP 189,159 68 15% 16% JBI Liu et al., 2021 CP 4,381 22 38% 38% 48% MNOS Lao et al., 2020 CP 2,206 8 44% NA Liu et al., 2021b GP 146,139 71 33% 28% 30% NOS Chen et al., 2022 GP 201,953 82 34% STROBE Zhang et al., 2022 GP 203,552 25 22% 16% MMAT Pappa et al., 2022 GP 44,531 17 32% 34% STROBE Santabárbara et al., 2020 GP 44,531 17 32% 34% STROBE Santabárbara et al., 2020 GP 44,531 17 32% 34% STROBE Santabárbara et al., 2021b GP 56,679 43 25% JSW JBI	Deng et al., 2021a	CS	1,441,828	89	32%	34%	33%	NOS
Santabárbara et al., 2021d CS 6,141 15 35% JBI Santabárbara et al., 2021c CS 4,147 13 37% JBI Zhang et al., 2021 CS 203,678 31 24% 22% AHRQ Lasheras et al., 2020 CS 11,710 8 28% IBI NA Zhai et al., 2022 CS 128,536 38 24% NA NOS Deng et al., 2021b CP 5,153 31 47% 45% 34% NOS Cénat et al., 2021 CP 189,159 68 15% 16% JBI Liu et al., 2021 CP 4,381 22 38% 38% 48% MNOS Lao et al., 2020 CP 2,206 8 44% NA NA Liu et al., 2021b GP 146,139 71 33% 28% 30% NOS Chen et al., 2022 GP 1,704,072 341 27% 30% MMAT	Liyanage et al., 2021	CS	1,088,619	36	41%			JBI
Santabárbara et al., 2021c CS 4,147 13 37% JBI Zhang et al., 2021 CS 203,678 31 24% 22% AHRQ Lasheras et al., 2020 CS 11,710 8 28% IBI Zhai et al., 2022 CS 128,536 38 24% NA Deng et al., 2021b CP 5,153 31 47% 45% 34% NOS Cénat et al., 2021 CP 189,159 68 15% 16% JBI Liu et al., 2021 CP 4,381 22 38% 38% 48% MNOS Lao et al., 2020 CP 2,206 8 44% NA NA Liu et al., 2021b GP 146,139 71 33% 28% 30% NOS Chen et al., 2022 GP 1,704,072 341 27% 30% MMAT Balakrishnan et al., 2022 GP 201,953 82 34% 35% 35% MMAT <t< td=""><td>Luo et al., 2021</td><td>CS</td><td>1,292,811</td><td>84</td><td></td><td>26%</td><td></td><td>JBI</td></t<>	Luo et al., 2021	CS	1,292,811	84		26%		JBI
Zhang et al., 2021 CS 203,678 31 24% 22% AHRQ Lasheras et al., 2020 CS 11,710 8 28% IBI Zhai et al., 2022 CS 128,536 38 24% NA Deng et al., 2021b CP 5,153 31 47% 45% 34% NOS Cénat et al., 2021 CP 189,159 68 15% 16% IBI Liu et al., 2021 CP 4,381 22 38% 38% 48% MNOS Lao et al., 2020 CP 2,206 8 44% NA Liu et al., 2021b GP 146,139 71 33% 28% 30% NOS Chen et al., 2022 GP 1,704,072 341 27% 30% MMAT Balakrishnan et al., 2022 GP 201,953 82 34% 5TROBE Zhang et al., 2022 GP 196,950 62 35% 35% 35% MMAT Pappa et al., 2022 GP 20,352 25 22% 16% MMAT	Santabárbara et al., 2021d	CS	6,141	15	35%			JBI
Lasheras et al., 2020 CS 11,710 8 28% JBI Zhai et al., 2022 CS 128,536 38 24% NA Deng et al., 2021b CP 5,153 31 47% 45% 34% NOS Cénat et al., 2021 CP 189,159 68 15% 16% JBI Liu et al., 2021 CP 4,381 22 38% 38% 48% MNOS Lao et al., 2020 CP 2,206 8 44% NA Liu et al., 2021b GP 146,139 71 33% 28% 30% NOS Chen et al., 2022 GP 1,704,072 341 27% 30% MMAT Balakrishnan et al., 2022 GP 201,953 82 34% 35% 35% 35% MMAT Pappa et al., 2022 GP 196,950 62 35% 35% 35% MMAT Pappa et al., 2022 GP 20,352 25 22% 16% MMAT Salari et al., 2020a GP 44,531 17 32% 34% STROBE Santabárbara et al., 2021b GP 56,679 43 25% JBI	Santabárbara et al., 2021c	CS	4,147	13		37%		JBI
Zhai et al., 2022 CS 128,536 38 24% NA Deng et al., 2021b CP 5,153 31 47% 45% 34% NOS Cénat et al., 2021 CP 189,159 68 15% 16% JBI Liu et al., 2021 CP 4,381 22 38% 38% 48% MNOS Lao et al., 2020 CP 2,206 8 44% NA Liu et al., 2021b GP 146,139 71 33% 28% 30% NOS Chen et al., 2022 GP 1,704,072 341 27% 30% MMAT Balakrishnan et al., 2022 GP 201,953 82 34% STROBE Zhang et al., 2022 GP 196,950 62 35% 35% 35% MMAT Pappa et al., 2022 GP 20,352 25 22% 16% MMAT Salari et al., 2020a GP 44,531 17 32% 34% STROBE <t< td=""><td>Zhang et al., 2021</td><td>CS</td><td>203,678</td><td>31</td><td>24%</td><td>22%</td><td></td><td>AHRQ</td></t<>	Zhang et al., 2021	CS	203,678	31	24%	22%		AHRQ
Deng et al., 2021b CP 5,153 31 47% 45% 34% NOS Cénat et al., 2021 CP 189,159 68 15% 16% JBI Liu et al., 2021 CP 4,381 22 38% 38% 48% MNOS Lao et al., 2020 CP 2,206 8 44% NA NA Liu et al., 2021b GP 146,139 71 33% 28% 30% NOS Chen et al., 2022 GP 1,704,072 341 27% 30% MMAT Balakrishnan et al., 2022 GP 201,953 82 34% STROBE Zhang et al., 2022 GP 196,950 62 35% 35% 35% MMAT Pappa et al., 2022 GP 20,352 25 22% 16% MMAT Salari et al., 2020a GP 44,531 17 32% 34% STROBE Santabárbara et al., 2021b GP 56,679 43 25%	Lasheras et al., 2020	CS	11,710	8	28%			JBI
Cénat et al., 2021 CP 189,159 68 15% 16% JBI Liu et al., 2021 CP 4,381 22 38% 38% 48% MNOS Lao et al., 2020 CP 2,206 8 44% NA Liu et al., 2021b GP 146,139 71 33% 28% 30% NOS Chen et al., 2022 GP 1,704,072 341 27% 30% MMAT Balakrishnan et al., 2022 GP 201,953 82 34% 5TROBE Zhang et al., 2022 GP 196,950 62 35% 35% 35% MMAT Pappa et al., 2022 GP 20,352 25 22% 16% MMAT Salari et al., 2020a GP 44,531 17 32% 34% STROBE Santabárbara et al., 2021b GP 56,679 43 25% 5 5 18 5 18 5 18 5 18 18 5 18 </td <td>Zhai et al., 2022</td> <td>CS</td> <td>128,536</td> <td>38</td> <td>24%</td> <td></td> <td></td> <td>NA</td>	Zhai et al., 2022	CS	128,536	38	24%			NA
Liu et al., 2021 CP 4,381 22 38% 38% 48% MNOS Lao et al., 2020 CP 2,206 8 44% NA Liu et al., 2021b GP 146,139 71 33% 28% 30% NOS Chen et al., 2022 GP 1,704,072 341 27% 30% MMAT Balakrishnan et al., 2022 GP 201,953 82 34% STROBE Zhang et al., 2022 GP 196,950 62 35% 35% 35% MMAT Pappa et al., 2022 GP 20,352 25 22% 16% MMAT Salari et al., 2020a GP 44,531 17 32% 34% STROBE Santabárbara et al., 2021b GP 56,679 43 25% 5% 5 18	Deng et al., 2021b	CP	5,153	31	47%	45%	34%	NOS
Lao et al., 2020 CP 2,206 8 44% NA Liu et al., 2021b GP 146,139 71 33% 28% 30% NOS Chen et al., 2022 GP 1,704,072 341 27% 30% MMAT Balakrishnan et al., 2022 GP 201,953 82 34% STROBE Zhang et al., 2022 GP 196,950 62 35% 35% 35% MMAT Pappa et al., 2022 GP 20,352 25 22% 16% MMAT Salari et al., 2020a GP 44,531 17 32% 34% STROBE Santabárbara et al., 2021b GP 56,679 43 25% 5 5 11 11 11 12 </td <td>Cénat et al., 2021</td> <td>CP</td> <td>189,159</td> <td>68</td> <td>15%</td> <td>16%</td> <td></td> <td>JBI</td>	Cénat et al., 2021	CP	189,159	68	15%	16%		JBI
Liu et al., 2021b GP 146,139 71 33% 28% 30% NOS Chen et al., 2022 GP 1,704,072 341 27% 30% MMAT Balakrishnan et al., 2022 GP 201,953 82 34% STROBE Zhang et al., 2022 GP 196,950 62 35% 35% 35% MMAT Pappa et al., 2022 GP 20,352 25 22% 16% MMAT Salari et al., 2020a GP 44,531 17 32% 34% STROBE Santabárbara et al., 2021b GP 56,679 43 25% 5 5 18	Liu et al., 2021	CP	4,381	22	38%	38%	48%	MNOS
Chen et al., 2022 GP 1,704,072 341 27% 30% MMAT Balakrishnan et al., 2022 GP 201,953 82 34% STROBE Zhang et al., 2022 GP 196,950 62 35% 35% 35% MMAT Pappa et al., 2022 GP 20,352 25 22% 16% MMAT Salari et al., 2020a GP 44,531 17 32% 34% STROBE Santabárbara et al., 2021b GP 56,679 43 25% U JBI		CP	2,206	8		44%		NA
Balakrishnan et al., 2022 GP 201,953 82 34% STROBE Zhang et al., 2022 GP 196,950 62 35% 35% 35% MMAT Pappa et al., 2022 GP 20,352 25 22% 16% MMAT Salari et al., 2020a GP 44,531 17 32% 34% STROBE Santabárbara et al., 2021b GP 56,679 43 25% Image: Control of the	Liu et al., 2021b	GP	146,139	71	33%	28%	30%	NOS
Zhang et al., 2022 GP 196,950 62 35% 35% 35% MMAT Pappa et al., 2022 GP 20,352 25 22% 16% MMAT Salari et al., 2020a GP 44,531 17 32% 34% STROBE Santabárbara et al., 2021b GP 56,679 43 25% JBI								
Zhang et al., 2022 GP 196,950 62 35% 35% 35% MMAT Pappa et al., 2022 GP 20,352 25 22% 16% MMAT Salari et al., 2020a GP 44,531 17 32% 34% STROBE Santabárbara et al., 2021b GP 56,679 43 25% JBI	Balakrishnan et al., 2022	GP	201,953	82		34%		STROBE
Pappa et al., 2022 GP 20,352 25 22% 16% MMAT Salari et al., 2020a GP 44,531 17 32% 34% STROBE Santabárbara et al., 2021b GP 56,679 43 25% JBI					35%		35%	
Salari et al., 2020a GP 44,531 17 32% 34% STROBE Santabárbara et al., 2021b GP 56,679 43 25% JBI	•							
Santabárbara et al., 2021b GP 56,679 43 25% JBI	**							
						28%	28%	
Necho et al., 2021 GP 63,439 16 38% 34% NOS	· ·							

HCW, healthcare worker; CS, College student; CP, COVID-19 patient; GP, general population; AHRQ, agency for healthcare research and quality; AMSTAR-2, A measurement tool to assess systematic reviews; JBI, Joanna Briggs institute tool; MMAT, mixed methods appraisal tool; STROBE, strengthening the reporting of observational studies in epidemiology; NOS, Newcastle-Ottawa Scale; NIH, National Institutes of Health quality assessment tool; ROSBIN I risk of bias in non-randomized studies of interventions; MNOS modified form of the Newcastle-Ottawa scale; NA, not assessment.

TABLE 2 A measurement tool to assess systematic reviews (AMSTAR 2) score for methodological quality of included systematic reviews.

Included studies	Item 1	Item 2	Item 3	Item 4	Item 5	Item 6	Item 7	Item 8	Item 9	Item 10	Item 11	Item 12	Item 13	Item 14	Item 15	Item 16	Total score
Pappa et al.,	Y	Y	N	Y	Y	Y	Y	N	Y	N	Y	Y	Y	Y	N	Y	12
Al Maqbali et al., 2021	Y	Y	N	Y	Y	Y	Y	N	Y	N	Y	Y	Y	Y	N	Y	12
Varghese et al., 2021	Y	Y	N	Y	N	N	Y	N	Y	N	Y	Y	N	Y	N	Y	9
Ślusarska et al., 2022	Y	Y	N	Y	N	Y	Y	Y	Y	N	Y	Y	N	Y	N	Y	10
Salari et al., 2020b	Y	Y	N	N	Y	N	Y	N	Y	N	Y	Y	N	Y	Y	Y	9
Li et al., 2021	Y	Y	N	Y	N	N	Y	N	Y	N	Y	Y	Y	Y	Y	Y	10
Marvaldi et al., 2021	Y	Y	N	Y	N	N	Y	N	Y	N	Y	Y	N	Y	Y	Y	9
Saragih et al., 2021	Y	Y	N	Y	N	N	Y	Y	Y	N	Y	Y	N	Y	N	Y	9
Batra et al., 2020	Y	Y	N	Y	Y	Y	Y	Y	Y	N	Y	Y	N	Y	Y	Y	12
Santabárbara et al., 2021a	Y	Y	N	Y	Y	N	Y	Y	Y	N	Y	Y	N	Y	N	Y	10
Norhayati et al., 2021	Y	Y	N	Y	Y	Y	Y	Y	Y	N	Y	Y	N	Y	N	Y	11
Sahebi et al., 2021	Y	Y	N	Y	Y	N	Y	N	Y	N	Y	Y	N	Y	N	Y	9
Salari et al., 2020c	Y	Y	N	Y	Y	N	Y	Y	Y	N	Y	Y	Y	Y	Y	Y	12
Johns et al., 2022	Y	Y	N	Y	Y	Y	Y	Y	Y	N	Y	Y	Y	Y	Y	Y	13
Hu et al., 2022	Y	Y	N	Y	Y	N	Y	N	Y	N	Y	Y	Y	Y	N	Y	10
Jahrami et al., 2021	Y	Y	N	Y	Y	Y	Y	Y	Y	N	Y	Y	Y	Y	Y	Y	13
Serrano- Ripoll et al., 2020	Y	Y	N	Y	N	Y	Y	Y	Y	N	Y	Y	N	Y	Y	Y	11
Serrano- Ripoll et al., 2021	Y	Y	N	Y	Y	N	Y	Y	Y	N	Y	Y	N	Y	Y	Y	11
Liu et al., 2021a	Y	Y	N	Y	N	Y	Y	N	Y	N	Y	Y	Y	Y	Y	Y	12
Mulyadi et al., 2021	Y	Y	N	Y	Y	Y	Y	N	Y	N	Y	Y	N	Y	Y	Y	12
Chang et al., 2021	Y	Y	N	N	N	Y	Y	N	Y	N	Y	Y	Y	Y	Y	Y	10
Deng et al., 2021a	Y	Y	N	Y	Y	N	Y	N	Y	N	Y	Y	Y	Y	Y	Y	11
Liyanage et al., 2021	Y	Y	N	Y	Y	N	Y	N	Y	N	Y	Y	Y	Y	N	Y	10
Luo et al., 2021	Y	Y	N	Y	N	N	Y	N	Y	N	Y	Y	N	Y	Y	Y	9
Santabárbara et al., 2021d	Y	Y	N	Y	Y	N	Y	N	Y	N	Y	Y	Y	Y	Y	Y	11
Santabárbara et al., 2021d	Y	Y	N	Y	Y	N	Y	N	Y	N	Y	Y	Y	Y	Y	Y	11
Zhang et al., 2021	Y	Y	N	Y	Y	Y	Y	Y	Y	N	Y	Y	N	Y	N	Y	11
Lasheras et al., 2020	Y	Y	N	Y	Y	Y	Y	Y	Y	N	Y	Y	Y	Y	Y	Y	13

TABLE 2 (Continued)

Included studies	Item 1	Item 2	Item 3	Item 4	Item 5	Item 6	Item 7	Item 8	Item 9	Item 10	Item 11	Item 12	Item 13	Item 14	Item 15	Item 16	Total score
Zhai et al., 2022	Y	N	N	Y	N	Y	N	N	Y	N	Y	Y	Y	Y	Y	Y	10
Deng et al., 2021b	Y	Y	N	Y	Y	Y	Y	N	Y	N	Y	Y	Y	Y	Y	Y	12
Cénat et al., 2021	Y	Y	N	N	N	N	Y	N	Y	N	Y	Y	Y	Y	Y	Y	9
Liu et al., 2021	Y	Y	N	Y	N	N	Y	N	Y	N	Y	Y	N	Y	N	Y	8
Lao et al., 2020	Y	Y	N	Y	N	N	Y	N	Y	N	Y	Y	N	Y	N	Y	8
Liu et al., 2021b	Y	N	N	Y	N	Y	N	N	Y	N	Y	Y	Y	Y	Y	Y	10
Chen et al., 2022	Y	Y	N	Y	N	N	Y	N	Y	N	Y	Y	Y	Y	Y	Y	11
Balakrishnan et al., 2022	Y	Y	N	N	N	Y	Y	N	Y	N	Y	Y	Y	Y	Y	Y	11
Zhang et al., 2022	Y	Y	N	N	Y	Y	Y	Y	Y	N	Y	Y	N	Y	N	Y	11
Pappa et al., 2022	Y	Y	N	Y	N	Y	Y	Y	Y	N	Y	Y	Y	Y	Y	Y	13
Salari et al., 2020a	Y	Y	N	Y	Y	N	Y	N	Y	N	Y	Y	N	Y	N	Y	10
Santabárbara et al., 2021b	Y	Y	N	Y	Y	Y	Y	Y	Y	N	Y	Y	Y	Y	Y	Y	14
Nochaiwong et al., 2021	Y	Y	N	Y	Y	Y	Y	Y	Y	N	Y	Y	Y	Y	Y	Y	14
Necho et al., 2021	Y	Y	N	Y	N	Y	Y	N	Y	N	Y	Y	Y	Y	Y	Y	12

Y, when the criterion is explicitly met; N, when the criterion is explicitly not met.

 $Item \ 1 \ Did \ the \ research \ questions \ and \ inclusion \ criteria \ for \ the \ review \ include \ the \ components \ of \ PICO?$

Item 2 Did the report of the review contain an explicit statement that the review methods were established prior to the conduct of the review and did the report justify any significant deviations from the protocol?

Item 3 Did the review authors explain their selection of the study designs for inclusion in the review?

Item 4 Did the review authors use a comprehensive literature search strategy?

Item 5 Did the review authors perform study selection in duplicate?

Item 6 Did the review authors perform data extraction in duplicate?

 $Item\ 7\ Did\ the\ review\ authors\ provide\ a\ list\ of\ excluded\ studies\ and\ justify\ the\ exclusions?$

Item 8 Did the review authors describe the included studies in adequate detail?

Item 9 Did the review authors use a satisfactory technique for assessing the risk of bias (RoB) in individual studies that were included in the review?

Item 10 Did the review authors report on the sources of funding for the studies included in the review?

 $Item \ 11 \ If \ meta-analysis \ was \ performed, \ did \ the \ review \ authors \ use \ appropriate \ methods \ for \ statistical \ combination \ of \ results?$

Item 12 If meta-analysis was performed, did the review authors assess the potential impact of RoB in individual studies on the results of the meta-analysis or other evidence synthesis? Item 13 Did the review authors account for RoB in primary studies when interpreting/discussing the results of the review? Item 14 Did the review authors provide a satisfactory explanation for, and discussion of, any heterogeneity observed in the results of the review?

Item 15 If they performed quantitative synthesis did the review authors carry out an adequate investigation of publication bias (small study bias) and discuss its likely impact on the results of the review?

Item 16 Did the review authors report any potential sources of conflict of interest, including any funding they received for conducting the review?

Characteristics of included systematic reviews/meta-analyses

Table 1 summarizes the general characteristics of the 42 SRs/MAs included (year of publication and authors, number of included studies, total sample size, outcome indicators and prevalence, quality assessment tools, and journal of publication). A total of 40 of the SRs/MAs were published

in English and the remaining two were in Chinese. Of these 42 SRs/MAs, 19 were reported by HCWs, 10 by CSs, four by CPs and nine by the GPs. Among the 42 SRs/MAs, 36 used quality assessment tools, of which JBI was the most common assessment tool, with five SRs/MAs using AHRQ, followed by one using AMSTAR-2, 12 using JBI, three using MMAT, one using MNOS, eight using NOS, one using ROBINS I, and four using STROBE. The

outcome indicators observed in our study were mainly anxiety, depression and insomnia, and not all SRs/MAs included contained these three indicators. There were 34 SRs/MAs on anxiety, with a total of 6,028,108 samples reporting a comorbidity of anxiety, 31 on depression, with a total of 6,200,110 samples reporting a comorbidity of depression, and 18 on insomnia, with a total of 492,314 samples reporting a comorbidity of insomnia.

The methodological quality of included systematic reviews/meta-analyses

The methodological quality of the 42 SRs/MAs included in the overview was evaluated using the AMSTAR 2 tool and the results are presented in the Table 2. the median AMSTAR 2 score was 11. of these 42 SRs/MAs, a total of 13 SRs/MAs met and partially met \geq 70% of the entries, indicating high quality. For each entry of the AMSTAR 2 tool, the satisfaction was: item 1 (42/42, 100%), item 2 (40/42, 95.2%), item 3 (0/42, 0%), item 4 (37/42, 88.1%), item 5 (24/42, 57.1%), item 6 (22/42, 52.4%), item 7 (40/42, 95.2%), item 8 (16/42, 38.1%), item 9 (42/42, 100%), item 10 (0/42, 0%), item 11 (42/42, 100%), item 12 (42/42, 100%), item 13 (24/42, 57.1%), item 14 (42/42, 100%), item 15 (27/42, 64.3%), item 16 (42/42, 100%). The methodological quality of each SRs/MAs varied greatly and had some limitations. Among them, items 1, 9, 11, 12, 14, and 16 could be satisfied in each report. However, items 3 and 10 were poorly satisfied. The rest of the items were satisfied to vary degrees per SRs/MAs. Thirteen SRs/MAs were rated as "medium" for methodological quality, 13 were rated as "low," and 16 were rated as "very low." Subsequently, we visualized the quality assessment results using bubble plot (see Figure 3).

Subgroup analysis of psychological disorder symptoms

Anxiety

A total of 34 SRs/MAs on the prevalence of anxiety are available. The prevalence of anxiety in different populations during the COVID-19 pandemic is analyzed in this overview (see **Figure 4**). Significance tests of the results of the group comparisons revealed no statistically significant differences (p = 0.94). In the HCWs population, the results of 15 SRs/MAs were summarized and the interval of anxiety prevalence was found to be 20–44%, among which Batra et al. (2020), Liu et al. (2021a) and Saragih et al. (2021) reported significantly higher prevalence of anxiety in HCWs than others. Liu et al. (2021a) study subjects were all from the sentinel hospital (a hospital that concentrates mainly on treating CPs), and the work pressure of HCWs in this hospital was higher, resulting in a higher prevalence of anxiety. In the CSs group, a summary of eight

reports found a prevalence range of 24–41%. In the CPs cohort, three reports had a prevalence range of 15–47%, and the results of these three reports differed significantly. The meta-analysis of Deng et al. (2021b) had a high AMSTAR 2 score and high confidence in the outcome. the reports of Cénat et al. (2021) and Liu et al. (2021) were "very low" quality studies in terms of methodological quality assessment and both reports had problems with literature search, data extraction and publication bias, resulting in low credibility of the final results. In the GPs population, a summary of the results of eight SRs/MAs found a prevalence range of 22–38%.

Depression

A total of 30 SRs/MAs on the prevalence of depression are presented in this overview to analyze the prevalence of depression in different populations during the COVID-19 pandemic (see Figure 5). The results of the comparison between groups were statistically significantly different (p < 0.05). In the HCWs group, the results of 14 SRs/MAs were summarized and the range of depression prevalence was found to be 22-38%. In the CSs group, summarizing the results of six SRs/MAs found a depression prevalence interval of 22-52%. The results of the meta-analysis by Mulyadi et al. (2021) differed from the others, but the study had a better qualitative assessment and higher confidence. We analyzed the reason for this and found that unlike others the study was conducted with all nursing medical students. The authors of this article explain that nursing students had a high prevalence of depression before the COVID-19 pandemic, probably due to educational and family factors, and that there was a significant increase in prevalence during the pandemic. The intervals of depression prevalence were 38-45% and 16-35% in the CPs and GPs groups, respectively.


Insomnia

There were 18 SRs/MAs on the prevalence of insomnia in different groups (HCWs, CSs, CPs, GPs). The results of the comparison between groups were statistically significantly different (p < 0.05). Summary results found that the intervals of insomnia prevalence were 28–45%, 27–33%, 34–48%, 28–35%, respectively (see **Figure 6**).

Discussion

Statement of main findings

The prevalence of psychological disorders in various populations increased significantly during the COVID-19 pandemic (Pfefferbaum and North, 2020), and the purpose of this review was to assess the methodological quality of the SRs/MAs and to provide an description of the occurrence of anxiety, depression, and insomnia in different populations. We performed a meta-analysis of the prevalence of anxiety,



depression and insomnia in the target study population. We found that the prevalence of anxiety in the different subgroups were: HCWs (20-44%), CSs (24-41%), CPs (15-47%), and GPs (22-38%), but there were no statistically significant differences between this subgroup comparison (p = 0.94). The prevalence of depression were: HCWs (22-38%), CSs (22-52%), CPs (38-45%), and GPs (16-35%). Our results show that the prevalence of depression is higher in CPs and CSs than in the rest of the population, with a statistically significant difference in the comparison between this subgroup (p < 0.05). We need to pay extra attention to the mental health problems of CSs. Chen et al. argued that adolescents are immature and belong to a vulnerable group, and that CSs are prone to depressive symptoms and subsequent development of depression after the outbreak of the new crown pandemic, when they spend long periods of time taking courses online and doing related activities indoors, and this change in lifestyle and the threat of possible infection (Chen F. et al., 2020). In terms of insomnia-related prevalence, the results for the different subgroups were: HCWs (28-45%), CSs (27-33%), CPs (34-48%), and GPs (28-35%), with statistically significant differences (p < 0.05). We then tested the heterogeneity of the included studies, first using a fixed-effects model for heterogeneity, and the results showed ($I^2 > 50\%$) a large heterogeneity among studies, and then we changed to a random-effects model, where the same heterogeneity existed. This may be due to the fact that the included SRs/MAs were from studies conducted by scholars in various countries around the world, and since the pandemic was global in nature, the raw data for the included SRs/MAs were from different countries and regions. The severity of the epidemic and prevention and control measures vary from country to country, resulting in differences in the prevalence of mental illness in the population, so there is a high degree of heterogeneity among

studies. However, the purpose of our study was to summarize the prevalence of anxiety, depression, and insomnia in key populations worldwide during the COVID-19 pandemic, so the presence of heterogeneity was unavoidable for our study purpose and did not substantially affect our study purpose. For the results of inter-group comparison of insomnia prevalence, we found that patients with COVID-19 were the population with the highest occurrence of psychological disorders, and sleep disorders continued to be the most common psychological disorder in patients with COVID-19, possibly due to the core symptoms of COVID-19 including cough, fever and dyspnea, all of which are associated with sleep problems (Ferrando et al., 2016; Huang et al., 2020). It has been suggested that the higher risk of sleep problems in CPs may also be attributable to physical pain and side effects of medications used to treat the virus (Shi et al., 2020). The overall analysis showed that the prevalence of insomnia was the highest, and a previous meta-analysis showed that the bulk of sleep disorders in the GP was only 15% during non-COVID-19 pandemics (Cao et al., 2017). It has been suggested that the reason why insomnia is more common is because of the potential bidirectional relationship between sleep and psychiatric co-morbidities, especially when more comorbidities are present (e.g., anxiety and depression), which suggests that sleep specialists treating this suggests that sleep specialists should consider psychiatric co-morbidities when treating sleep problems, and vice versa (Jahrami et al., 2021).

Our results indicate that insomnia-related symptoms were more common in different populations during the new crown epidemic relative to anxiety and depression. A previous meta-analysis showed that the bulk of sleep disorders in the GP was only 15% during non-COVID-19 pandemics (Cao et al., 2017). It has been suggested that the reason why insomnia is more common is because of the potential bidirectional relationship


Study or Subgroup	Risk Difference	SF	Weight	Risk Difference IV, Random, 95% CI	Risk Difference IV, Random, 95% Cl	
1.1.1 HCW	Tuok Dilloronoo	- JL	wongin	TV T CONTROL OF TO	TWO TRAINED IN CO.	
Al Magbali M 2021	0.37	0.00169056	6.7%	0.37 [0.37, 0.37]		
Batra K 2020		0.00209133	6.7%	0.34 [0.34, 0.34]		
Hu N 2022		0.00203155	6.7%	0.35 [0.34, 0.36]		
		0.00328288	6.7%			
Johns G 2022				0.20 [0.20, 0.20]		
Liu X 2021b		0.00132995	6.7%	0.22 [0.22, 0.22]		
Li Y 2021		0.00253404	6.7%	0.44 [0.44, 0.44]		
Marvaldi M 2021		0.00201071	6.7%	0.30 [0.30, 0.30]		
Norhayati M N 2021		0.00134778	6.7%	0.35 [0.35, 0.35]		
Pappa S 2020		0.0023218	6.7%	0.23 [0.23, 0.23]		
Salari N 2020b		0.00311193	6.7%	0.26 [0.25, 0.27]		
Santabárbara J 2021a		0.00180689	6.7%	0.25 [0.25, 0.25]		
Saragih I D 2021		0.00211241	6.7%	0.40 [0.40, 0.40]		
Serrano-Ripoll 2020		0.00168576	6.7%	0.30 [0.30, 0.30]		
Slusarska B 2022		0.00215918	6.7%	0.29 [0.29, 0.29]		
Varghese A 2021	0.33	0.00402598	6.7%	0.33 [0.32, 0.34]		
Subtotal (95% CI)			100.0%	0.31 [0.27, 0.34]	■ ■	
Heterogeneity: Tau ² = 0.1			0.00001)	; I*= 100%		
Test for overall effect: Z =	= 17.41 (P < 0.0000	1)				
1.1.2 CS						
Chang J J 2021		0.00121873		0.31 [0.31, 0.31]	•	
Deng J 2021a	0.32	0.00044594	12.5%	0.32 [0.32, 0.32]	•	
Isabel Lasheras 2020	0.28	0.00420766	12.5%	0.28 [0.27, 0.29]	•	
Liyanage S 2022	0.41	0.00047139	12.5%	0.41 [0.41, 0.41]	•	
Mulyadi M 2021	0.32	0.00405294	12.5%	0.32 [0.31, 0.33]	•	
Santabárbara J 2021d	0.35	0.00608655	12.4%	0.35 [0.34, 0.36]	•	
Zhai W H 2022	0.24	0.00119124	12.5%	0.24 [0.24, 0.24]	•	
Zhang Y 2021	0.24	0.00094633	12.5%	0.24 [0.24, 0.24]	•	
Subtotal (95% CI)			100.0%	0.31 [0.26, 0.36]	•	
Heterogeneity: Tau² = 0.1 Test for overall effect: Z =			.00001);	²=100%		
1.1.3 CP						
Cénat J M 2021	0.1515	0.00102913	33.4%	0.15 [0.15, 0.15]		
Deng J 2021b	0.47	0.0046122	33.3%	0.47 [0.46, 0.48]		
Liu C 2021a		0.00988938	33.3%	0.38 [0.36, 0.40]		
Subtotal (95% CI)	0.00		100.0%	0.33 [0.09, 0.58]		-
Heterogeneity: Tau² = 0.1 Test for overall effect: Z =		df= 2 (P < 0.0)0001); l²			
1.1.4 GP						
Chen J 2022	0.27	0.00034009	12.5%	0.27 [0.27, 0.27]		
Liu X 2021c		0.00159809	12.5%	0.33 [0.32, 0.33]		
Necho M 2021	0.3812	0.0019283	12.5%	0.38 [0.38, 0.38]		
Nochaiwong S 2021		0.00082088	12.5%	0.26 [0.26, 0.26]		
Pappa S 2022		0.00290372	12.5%	0.22 [0.21, 0.23]	•	
Salari N 2020a		0.00185051	12.5%	0.32 [0.32, 0.32]		
Santabárbara J 2021b		0.00181882	12.5%	0.25 [0.25, 0.25]		
Zhang S X 2022		0.00133286	12.5%	0.35 [0.35, 0.35]		
Subtotal (95% CI)	0.33	5.00155200	100.0%	0.30 [0.27, 0.32]	•	
Heterogeneity: Tau² = 0.1	nn- ∩hiz – ggg# nc	df = 7/D < 0.0				
Test for overall effect: Z=			,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,	- 10070		
				_	-0.5 -0.25 0 0.25 0.	5
Test for subaroup differe	ences: Chi² = 0.40.	df=3 (P=0.9	4). I² = 0%	6		
URE 4						

between sleep and psychiatric co-morbidities, especially when more co-morbidities are present (e.g., anxiety and depression), which suggests that sleep specialists treating this suggests that sleep specialists should consider psychiatric co-morbidities when treating sleep problems, and vice versa (Jahrami et al., 2021). In addition, due to the lack of knowledge about the COVID-19 and the huge lethality caused by the lack of effective treatment measures at the beginning of the pandemic, patients

Study or Subgroup	Diok Difference	er.	Moinht	Risk Difference	Risk Difference
Study or Subgroup 2.1.1 HCW	Risk Difference	3E	vveigni	IV, Random, 95% CI	IV, Random, 95% CI
	0.25	0.00171007	2.200	0.25 (0.25 0.25)	
Al Maqbali M 2021		0.00171897	3.2%	0.35 [0.35, 0.35]	
Batra K 2020		0.00201975	3.2%	0.32 [0.32, 0.32]	_
Hu N 2022	0.38	0.0024363	3.2%	0.38 [0.38, 0.38]	
Johns G 2022		0.0024673	3.2%	0.26 [0.26, 0.26]	
Liu X 2021b		0.00132124	3.2%	0.22 [0.22, 0.22]	'
Li Y 2021		0.00236101	3.2%	0.31 [0.31, 0.31]	
Marvaldi M 2021		0.00177476	3.2%	0.31 [0.31, 0.31]	
Norhayati M N 2021		0.00130751	3.2%	0.35 [0.35, 0.35]	
Pappa S 2020		0.00230734	3.2%	0.23 [0.23, 0.23]	
Salari N 2020b	0.24	0.00308	3.2%	0.24 [0.23, 0.25]	•
Saragih I D 2021	0.37	0.00208183	3.2%	0.37 [0.37, 0.37]	
Serrano-Ripoll 2020	0.24	0.00168344	3.2%	0.24 [0.24, 0.24]	•
Ślusarska B 2022	0.22	0.00197115	3.2%	0.22 [0.22, 0.22]	•
Varghese A 2021	0.32	0.0042071	3.2%	0.32 [0.31, 0.33]	
Subtotal (95% CI)			45.3%	0.29 [0.26, 0.33]	•
Heterogeneity: Tau ² = 0	.00; Chi² = 12642.58	3, df = 13 (P <	0.00001)	; I² = 100%	
Test for overall effect: Z	= 18.08 (P < 0.0000	1)			
2.1.2 CS					
Chang J J 2021	0.24	0.00128919	3.2%	0.34 [0.34, 0.34]	
_		0.00128919			
Deng J 2021a			3.2%	0.34 [0.34, 0.34] 0.36 [0.36, 0.36]	
Luo W 2021		0.00038578	3.2%	0.26 [0.26, 0.26]	
Mulyadi M 2021		0.00434074	3.2%	0.52 [0.51, 0.53]	
Santabárbara J 2021a		0.00822219	3.1%	0.37 [0.35, 0.39]	
Zhang Y 2021 Subtotal (95% CI)	0.22	0.00155581	3.2% 19.3 %	0.22 [0.22, 0.22] 0.34 [0.29, 0.39]	
Heterogeneity: Tau² = 0 Test for overall effect: Z			.00001);		
2.1.3 CP					
Deng J 2021b	0.45	0.00459737	3.2%	0.45 [0.44, 0.46]	•
Lao Y 2020		0.0105686	3.1%	0.44 [0.42, 0.46]	_
Liu C 2021a	0.38	0.00796251	3.1%	0.38 [0.36, 0.40]	•
Subtotal (95% CI)			9.4%	0.42 [0.38, 0.47]	▼
Heterogeneity: Tau ² = 0 Test for overall effect: Z)01);	37%	
2.1.4 GP					
Balakrishnan V 2022	0.34	0.00105411	3.2%	0.34 [0.34, 0.34]	•
Chen J 2022	0.3	0.00035105	3.2%	0.30 [0.30, 0.30]	•
Liu X 2021c	0.276	0.00148877	3.2%	0.28 [0.27, 0.28]	•
Necho M 2021	0.3431	0.00224972	3.2%	0.34 [0.34, 0.35]	•
Nochaiwong S 2021	0.28	0.00084761	3.2%	0.28 [0.28, 0.28]	•
Pappa S 2022	0.16	0.00310282	3.2%	0.16 [0.15, 0.17]	•
Salari N 2020a	0.337	0.00223996	3.2%	0.34 [0.33, 0.34]	•
Zhang S X 2022		0.00127677	3.2%	0.35 [0.35, 0.35]	
Subtotal (95% CI)			25.9%	0.30 [0.28, 0.32]	•
Heterogeneity: Tau² = 0 Test for overall effect: Z)0001); l²	= 100%	
Total (95% CI)			100.0%	0.32 [0.30, 0.33]	•
Heterogeneity: Tau ² = 0	.00; Chi² = 46728.80	0, df = 30 (P <	0.00001)	· ≥ = 100%	
Test for overall effect: Z Test for subgroup differ	= 40.02 (P < 0.0000	1)		-1	-0.5 Ö 0.5 1
5					

with the COVID-19 are filled with internal panic and fear for their lives (Gyasi, 2020), the lack of contact with the outside world during isolation or hospitalization, which makes them more likely to suffer from loneliness, anxiety and depression, and even suicidal thoughts (Kawohl and Nordt, 2020; Luchetti et al., 2020; Pappa et al., 2020; Varghese et al., 2021). The prevalence of psychological disorders among HCWs is also

higher, probably due to the huge workload during the pandemic, the enormous psychological pressure on HCWs, coupled with the fear of being infected by contact with CPs, as well as the need for a series of measures such as isolation when leaving the hospital, creating a very obvious psychological barrier for HCWs (Pappa et al., 2020; Al Maqbali et al., 2021; Marvaldi et al., 2021; Saragih et al., 2021; Varghese et al., 2021).



Methodological quality of systematic reviews

In terms of methodological quality, of the 42 SRs/MAs included, 16 were of very low-quality, the rest were of low-quality and moderate-quality, and there was no high-quality SRs/MAs. Problems were more pronounced in three areas: (1) The inclusion criteria for the type of study were not specified, only the inclusion of cross-sectional studies was described, and the reasons for the inclusion of study types were not explained; and (2) All studies only described the reasons for exclusion of literature without providing a detailed list of excluded literature; Also for the very low quality 16 SRs/MAs, the problems were mainly related to the impact on the risk of bias not being explained in the discussion. These results suggest that

the current SRs/MAs exploring the incidence of anxiety, depression, and insomnia in different populations during the pandemic generally follow the reporting norms. However, the methodological quality needs to be improved, and researchers still lack attention in explaining the type of study design, providing a list of excluded literature, and the reasons and sources of funding.

Strengths and limitations

This overview is the first study to assess the quality of evidence on the incidence of anxiety, depression, and insomnia in different populations during the COVID-19 pandemic using AMSTAR 2 tools. However, our study has some limitations. First, in this review, we included only SRs/MAs, while primary

studies (e.g., cohort studies, observational studies, and case-control studies) were not reviewed. Second, only Chinese and English literature were included in this study, relevant gray literature was not obtained, and the search results may be subject to publication bias. Third, the subjectivity of the evaluators in evaluating the literature may lead to bias and thus affect the evaluation results.

Conclusion

The evidence summarized in this paper suggests that the methodological quality of SRs/MAs is not high. Therefore, they should be improved using the AMSTAR 2 tool to provide effective evidence-based medicine for targeted psychological interventions, psychological counseling services, and adequate social support help to alleviate psychological disorders due to pandemic factors.

Data availability statement

The original contributions presented in this study are included in the article/Supplementary material, further inquiries can be directed to the corresponding author.

Author contributions

QZ and SS designed the study. QZ and YT searched the literature and performed screening. CJ and PL collected relevant data. QZ analyzed the data and drafted the manuscript. JT and

SS revised and approved the final version of the manuscript. All authors have read and approved the submitted version.

Funding

This project was supported by the COVID-19 Prevention and Control Technology Research Project of Lanzhou City (grant number: 2020-XG-56).

Conflict of interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher's note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Supplementary material

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fpsyg.2022.1024668/full#supplementary-material

References

Al Maqbali, M., Al Sinani, M., and Al-Lenjawi, B. (2021). Prevalence of stress, depression, anxiety and sleep disturbance among nurses during the COVID-19 pandemic: A systematic review and meta-analysis. J. Psychosom. Res. 141:110343. doi: 10.1016/j.jpsychores.2020.11

Alsubaie, M. M., Stain, H. J., Webster, L. A. D., and Wadman, R. (2019). The role of sources of social support on depression and quality of life for university students. *Int. J. Adolesc. Youth.* 24, 484–496. doi: 10.1080/02673843.2019.156 8887

Balakrishnan, V., Ng, K. S., Kaur, W., Govaichelvan, K., and Lee, Z. L. (2022). COVID-19 depression and its risk factors in Asia Pacific - A systematic review and meta-analysis. *J Affect Disord*. 298, 47–56. doi: 10.1016/j.jad.2021. 11.048

Bao, Y., Sun, Y., Meng, S., Shi, J., and Lu, L. (2020). 2019-nCoV epidemic: Address mental health care to empower society. *Lancet* 395, e37–e38. doi: 10.1016/S0140-6736(20)30309-3

Batra, K., Singh, T. P., Sharma, M., Batra, R., and Schvaneveldt, N. (2020). Investigating the psychological impact of COVID-19 among healthcare workers: A meta-analysis. *Int. J. Environ. Res. Public Health* 17:9096. doi: 10.3390/ijerph17239096

Browning, M., Larson, L. R., Sharaievska, I., Rigolon, A., McAnirlin, O., Mullenbach, L., et al. (2021). Psychological impacts from COVID-19 among university students: Risk factors across seven states in the United States. *PLoS One* 16:e0245327. doi: 10.1371/journal.pone.0245327

Cao, X. L., Wang, S. B., Zhong, B. L., Zhang, L., Ungvari, G. S., Ng, C. H., et al. (2017). The prevalence of insomnia in the general population in China: A meta-analysis. *PLoS One* 12:e0170772. doi: 10.1371/journal.pone.0170772

Cénat, J. M., Blais-Rochette, C., Kokou-Kpolou, C. K., Noorishad, P. G., Mukunzi, J. N., McIntee, S. E., et al. (2021). Prevalence of symptoms of depression, anxiety, insomnia, posttraumatic stress disorder, and psychological distress among populations affected by the COVID-19 pandemic: A systematic review and meta-analysis. *Psychiatry Res.* 295:113599. doi: 10.1016/j.psychres.2020.11

Chang, J. J., Ji, Y., Li, Y. H., Pan, H. F., and Su, P. Y. (2021). Prevalence of anxiety symptom and depressive symptom among college students during COVID-19 pandemic: A meta-analysis. *J. Affect Disord*. 292, 242–254. doi: 10.1016/j.jad.2021. 05.109

Chen, F., Zheng, D., Liu, J., Gong, Y., Guan, Z., and Lou, D. (2020). Depression and anxiety among adolescents during COVID-19: A cross-sectional study. *Brain Behav. Immun.* 88, 36–38. doi: 10.1016/j.bbi.2020.05.061

- Chen, J., Zhang, S. X., Yin, A., and Yáñez, J. A. (2022). Mental health symptoms during the COVID-19 pandemic in developing countries: A systematic review and meta-analysis. *J. Glob. Health* 12:05011. doi: 10.7189/jogh.12.05011
- Chen, Q., Liang, M., Li, Y., Guo, J., Fei, D., Wang, L., et al. (2020). Mental health care for medical staff in China during the COVID-19 outbreak. *Lancet Psychiatry* 7, e15–e16. doi: 10.1016/S2215-0366(20)30078-X
- Deng, J., Zhou, F., Hou, W., Silver, Z., Wong, C. Y., Chang, O., et al. (2021a). The prevalence of depressive symptoms, anxiety symptoms and sleep disturbance in higher education students during the COVID-19 pandemic: A systematic review and meta-analysis. *Psychiatry Res.* 301:113863. doi: 10.1016/j.psychres. 2021.113863
- Deng, J., Zhou, F., Hou, W., Silver, Z., Wong, C. Y., Chang, O., et al. (2021b). The prevalence of depression, anxiety, and sleep disturbances in COVID-19 patients: A meta-analysis. *Ann N Y Acad. Sci.* 1486, 90–111. doi: 10.1111/nyas.14506
- Ferrando, M., Bagnasco, D., Roustan, V., Canonica, G. W., Braido, F., and Baiardini, I. (2016). Sleep complaints and sleep breathing disorders in upper and lower obstructive lung diseases. *J. Thorac. Dis.* 8, E716–E725. doi: 10.21037/jtd. 2016.07.82
- Gyasi, R. M. (2020). Fighting COVID-19: Fear and internal conflict among older adults in ghana. *J. Gerontol. Soc. Work* 63, 688–690. doi: 10.1080/01634372.2020. 1766630
- Han, L., Wong, F., She, D., Li, S. Y., Yang, Y. F., Jiang, M. Y., et al. (2020). Anxiety and depression of nurses in a north west province in China during the period of novel coronavirus pneumonia outbreak. *J. Nurs. Scholarsh.* 52, 564–573. doi: 10.1111/jnu.12590
- Higgins, J. P. T., Thomas, J., Chandler, J., Cumpston, M., Li, T., Page, M. J., et al. (2020). Cochrane handbook for systematic reviews of interventions version 6.1 (updated September 2020). Available online at: www.training.cochrane.org/handbook (accessed June 5, 2022).
- Hu, N., Deng, H., Yang, H., Wang, C., Cui, Y., Chen, J., et al. (2022). The pooled prevalence of the mental problems of Chinese medical staff during the COVID-19 outbreak: A meta-analysis. *J. Affect Disord.* 303, 323–330. doi: 10.1016/j.jad.2022. 02.045
- Huang, C., Wang, Y., Li, X., Ren, L., Zhao, J., Hu, Y., et al. (2020). Clinical features of patients infected with 2019 novel coronavirus in Wuhan. China. *Lancet* 395, 497–506. doi: 10.1016/S0140-6736(20)30183-5
- Jahrami, H., BaHammam, A. S., Bragazzi, N. L., Saif, Z., Faris, M., and Vitiello, M. V. (2021). Sleep problems during the COVID-19 pandemic by population: A systematic review and meta-analysis. *J. Clin. Sleep Med.* 17, 299–313. doi: 10.5664/icsm.8930
- Johns, G., Samuel, V., Freemantle, L., Lewis, J., and Waddington, L. (2022). The global prevalence of depression and anxiety among doctors during the covid-19 pandemic: Systematic review and meta-analysis. *J. Affect Disord.* 298, 431–441. doi: 10.1016/j.jad.2021.11.026
- Kawohl, W., and Nordt, C. (2020). COVID-19, unemployment, and suicide. Lancet Psychiatry 7, 389-390. doi: 10.1016/S2215-0366(20)30141-3
- Lao, Y., Jiang, Y., Luo, X., and Liu, X. (2020). Focus on the depressive symptoms in COVID-19 patients: Perspective based on a rapid meta-analysis. *Asian J. Psychiatr.* 54:102421. doi: 10.1016/j.ajp.2020.102421
- Lasheras, I., Gracia-García, P., Lipnicki, D. M., Bueno-Notivol, J., López-Antón, R., de la Cámara, C., et al. (2020). Prevalence of anxiety in medical students during the COVID-19 Pandemic: A rapid systematic review with meta-analysis. *Int. J. Environ. Res. Public Health* 17:6603. doi: 10.3390/ijerph17186603
- Li, Y., Scherer, N., Felix, L., and Kuper, H. (2021). Prevalence of depression, anxiety and post-traumatic stress disorder in health care workers during the COVID-19 pandemic: A systematic review and meta-analysis. *PLoS One* 16:e0246454. doi: 10.1371/journal.pone.0246454
- Liu, C., Pan, W., Li, L., Li, B., Ren, Y., and Ma, X. (2021). Prevalence of depression, anxiety, and insomnia symptoms among patients with COVID-19: A meta-analysis of quality effects model. *J. Psychosom. Res.* 147:110516. doi: 10.1016/j.jpsychores.2021.110516
- Liu, X., Wang, G., Zhang, J., and Wang, S. (2021a). Prevalence of depression and anxiety among health care workers in designated hospitals during the COVID-19 epidemic: A meta-analysis. *Chin. J. Evidence Based Med.* 21, 1035–1042. doi: 10.7507/1672-2531.202105079
- Liu, X., Zhu, M., Zhang, R., Zhang, J., Zhang, C., Liu, P., et al. (2021b). Public mental health problems during COVID-19 pandemic: A large-scale meta-analysis of the evidence. *Transl. Psychiatry* 11:384. doi: 10.1038/s41398-021-01501-9
- Liyanage, S., Saqib, K., Khan, A. F., Thobani, T. R., Tang, W. C., Chiarot, C. B., et al. (2021). Prevalence of anxiety in university students during the COVID-19 Pandemic: A systematic review. *Int. J. Environ. Res. Public Health* 19:62. doi: 10.3390/ijerph19010062

- Lone, S. A., and Ahmad, A. (2020). COVID-19 pandemic an African perspective. *Emerg. Microb. Infect.* 9, 1300–1308. doi: 10.1080/22221751.2020.
- Luchetti, M., Lee, J. H., Aschwanden, D., Sesker, A., Strickhouser, J. E., Terracciano, A., et al. (2020). The trajectory of loneliness in response to COVID-19. *Am. Psychol.* 75, 897–908. doi: 10.1037/amp0000690
- Luo, W., Zhong, B. L., and Chiu, H. F. (2021). Prevalence of depressive symptoms among Chinese university students amid the COVID-19 pandemic: A systematic review and meta-analysis. *Epidemiol. Psychiatr. Sci.* 30:e31. doi: 10.1017/S2045796021000202
- Marvaldi, M., Mallet, J., Dubertret, C., Moro, M. R., and Guessoum, S. B. (2021). Anxiety, depression, trauma-related, and sleep disorders among healthcare workers during the COVID-19 pandemic: A systematic review and meta-analysis. *Neurosci. Biobehav. Rev.* 126, 252–264. doi: 10.1016/j.neubiorev.2021.03.024
- Mulyadi, M., Tonapa, S. I., Luneto, S., Lin, W. T., and Lee, B. O. (2021). Prevalence of mental health problems and sleep disturbances in nursing students during the COVID-19 pandemic: A systematic review and meta-analysis. *Nurs. Educ. Pract.* 57:103228. doi: 10.1016/j.nepr.2021.103228
- Necho, M., Tsehay, M., Birkie, M., Biset, G., and Tadesse, E. (2021). Prevalence of anxiety, depression, and psychological distress among the general population during the COVID-19 pandemic: A systematic review and meta-analysis. *Int. J. Soc. Psychiatry* 67, 892–906. doi: 10.1177/00207640211003121
- Nochaiwong, S., Ruengorn, C., Thavorn, K., Hutton, B., Awiphan, R., Phosuya, C., et al. (2021). Global prevalence of mental health issues among the general population during the coronavirus disease-2019 pandemic: A systematic review and meta-analysis. *Sci. Rep.* 11:10173. doi: 10.1038/s41598-021-89700-8
- Norhayati, M. N., Che Yusof, R., and Azman, M. Y. (2021). Prevalence of psychological impacts on healthcare providers during COVID-19 pandemic in Asia. *Int. J. Environ. Res. Public Health* 18:9157. doi: 10.3390/ijerph18179157
- Pappa, S., Chen, J., Barnett, J., Chang, A., Dong, R. K., Xu, W., et al. (2022). A systematic review and meta-analysis of the mental health symptoms during the Covid-19 pandemic in Southeast Asia. *Psychiatry Clin. Neurosci.* 76, 41–50. doi: 10.1111/pcn.13306
- Pappa, S., Ntella, V., Giannakas, T., Giannakoulis, V. G., Papoutsi, E., and Katsaounou, P. (2020). Prevalence of depression, anxiety, and insomnia among healthcare workers during the COVID-19 pandemic: A systematic review and meta-analysis. *Brain Behav. Immun.* 88, 901–907. doi: 10.1016/j.bbi.2020.05.026
- Pfefferbaum, B., and North, C. S. (2020). Mental health and the Covid-19 pandemic. N. Engl. J. Med. 383, 510–512. doi: 10.1056/NEJMp2008017
- Sahebi, A., Abdi, K., Moayedi, S., Torres, M., and Golitaleb, M. (2021). The prevalence of insomnia among health care workers amid the COVID-19 pandemic: An umbrella review of meta-analyses. *J. Psychosom. Res.* 149:110597. doi: 10.1016/j.jpsychores.2021.110597
- Salari, N., Hosseinian-Far, A., Jalali, R., Vaisi-Raygani, A., Rasoulpoor, S., Mohammadi, M., et al. (2020a). Prevalence of stress, anxiety, depression among the general population during the COVID-19 pandemic: A systematic review and meta-analysis. *Glob. Health* 16:57. doi: 10.1186/s12992-020-00589-w
- Salari, N., Khazaie, H., Hosseinian-Far, A., Ghasemi, H., Mohammadi, M., Shohaimi, S., et al. (2020b). The prevalence of sleep disturbances among physicians and nurses facing the COVID-19 patients: A systematic review and meta-analysis. *Glob. Health* 16:92. doi: 10.1186/s12992-020-00620-0
- Salari, N., Khazaie, H., Hosseinian-Far, A., Khaledi-Paveh, B., Kazeminia, M., Mohammadi, M., et al. (2020c). The prevalence of stress, anxiety and depression within front-line healthcare workers caring for COVID-19 patients: A systematic review and meta-regression. *Hum. Resour. Health* 18:100. doi: 1186/s12960-020-00544-1
- Santabárbara, J., Bueno-Notivol, J., Lipnicki, D. M., Olaya, B., Pérez-Moreno, M., Gracia-García, P., et al. (2021a). Prevalence of anxiety in health care professionals during the COVID-19 pandemic: A rapid systematic review (on published articles in Medline) with meta-analysis. *Prog. Neuropsychopharmacol. Biol. Psychiatry* 107:110244. doi: 10.1016/j.pnpbp.2021.110244
- Santabarbara, J., Idoiaga, N., Ozamiz-Etxebarria, N., and Bueno-Notivol, J. (2021d). Prevalence of anxiety in dental students during the COVID-19 Outbreak: A meta-analysis. *Int. J. Environ. Res. Public Health* 18:10978. doi: 10.3390/ijerph182010978
- Santabárbara, J., Lasheras, I., Lipnicki, D. M., Bueno-Notivol, J., Pérez-Moreno, M., López-Antón, R., et al. (2021b). Prevalence of anxiety in the COVID-19 pandemic: An updated meta-analysis of community-based studies. *Prog. Neuropsychopharmacol. Biol. Psychiatry* 109:110207. doi: 10.1016/j.pnpbp.2020.
- Santabárbara, J., Ozamiz-Etxebarria, N., Idoiaga, N., Olaya, B., and Bueno-Novitol, J. (2021c). Meta-Analysis of Prevalence of Depression in Dental

Students during COVID-19 Pandemic. Medicina (Kaunas) 57:1278. doi: 10.3390/medicina57111278

Saragih, I. D., Tonapa, S. I., Saragih, I. S., Advani, S., Batubara, S. O., Suarilah, I., et al. (2021). Global prevalence of mental health problems among healthcare workers during the Covid-19 pandemic: A systematic review and meta-analysis. *Int. J. Nurs. Stud.* 121:104002. doi: 10.1016/j.ijnurstu.2021. 104002

Serrano-Ripoll, M. J., Meneses-Echavez, J. F., Ricci-Cabello, I., Fraile-Navarro, D., Fiol-deRoque, M. A., Pastor-Moreno, G., et al. (2020). Impact of viral epidemic outbreaks on mental health of healthcare workers: A rapid systematic review and meta-analysis. *J. Affect Disord.* 277, 347–357. doi: 10.1016/j.jad.2020. 08 034

Serrano-Ripoll, M. J., Zamanillo-Campos, R., Castro, A., Fiol-de Roque, M. A., and Ricci-Cabello, I. (2021). Insomnia and sleep quality in healthcare workers fighting against COVID-19: A systematic review of the literature and meta-analysis. *Actas Esp Psiquiatr.* 49, 155–179.

Shea, B. J., Reeves, B. C., Wells, G., Thuku, M., Hamel, C., Moran, J., et al. (2017). AMSTAR 2: A critical appraisal tool for systematic reviews that include randomised or non-randomised studies of healthcare interventions, or both. *BMJ* 358:j4008. doi: 10.1136/bmj.j4008

Shi, L., Lu, Z. A., Que, J. Y., Huang, X. L., Liu, L., Ran, M. S., et al. (2020). Prevalence of and risk factors associated with mental health symptoms among the general population in china during the coronavirus disease 2019 Pandemic. *JAMA Netw. Open* 3:e2014053. doi: 10.1001/jamanetworkopen.2020.14053

Ślusarska, B., Nowicki, G. J., Niedorys-Karczmarczyk, B., and Chrzan-Rodak, A. (2022). prevalence of depression and anxiety in nurses during the first eleven months of the COVID-19 Pandemic: A systematic review and meta-analysis. *Int. J. Environ. Res. Public Health* 19:1154. doi: 10.3390/ijerph19031154

Varghese, A., George, G., Kondaguli, S. V., Naser, A. Y., Khakha, D. C., and Chatterji, R. (2021). Decline in the mental health of nurses across the globe during COVID-19: A systematic review and meta-analysis. *J. Glob. Health* 11:05009. doi: 10.7189/jogh.11.05009

Wang, C., Pan, R., Wan, X., Tan, Y., Xu, L., Ho, C. S., et al. (2020). Immediate psychological responses and associated factors during the initial stage of the 2019 Coronavirus Disease (COVID-19) epidemic among the general population in China. *Int. J. Environ. Res. Public Health* 17:1729. doi: 10.3390/ijerph17051729

Wang, J., Zhou, M., and Liu, F. (2020). Reasons for healthcare workers becoming infected with novel coronavirus disease 2019 (COVID-19) in China. *J. Hosp. Infect.* 105, 100–101. doi: 10.1016/j.jhin.2020.03.002

Wu, C., Hu, X., Song, J., Yang, D., Xu, J., Cheng, K., et al. (2020). Mental health status and related influencing factors of COVID-19 survivors in Wuhan. China. *Clin. Transl. Med.* 10:e52. doi: 10.1002/ctm2.52

Zhai, W., Zhang, Q., Hu, W., and Yan, J. (2022). A meta-analysis of anxiety symptom and related factors in chinese college students before and after the COVID-19 epidemic. *Chin. Ment. Health J.* 7, 626–632. doi: 10.3969/j.issn.1000-6729.2022.07.014

Zhang, S. X., Batra, K., Xu, W., Liu, T., Dong, R. K., Yin, A., et al. (2022). Mental disorder symptoms during the COVID-19 pandemic in Latin America - a systematic review and meta-analysis. *Epidemiol. Psychiatr. Sci.* 31:e23. doi: 10.1017/S2045796021000767

Zhang, W. R., Wang, K., Yin, L., Zhao, W. F., Xue, Q., Peng, M., et al. (2020). Mental Health and Psychosocial Problems of Medical Health Workers during the COVID-19 Epidemic in China. *Psychother. Psychosom.* 89, 242–250. doi: 10.1159/000507639

Zhang, Y., Bao, X., Yan, J., Miao, H., and Guo, C. (2021). Anxiety and Depression in Chinese Students During the COVID-19 Pandemic: A Meta-Analysis. *Front. Public Health* 9:697642. doi: 10.3389/fpubh.2021.697642